Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis

Table 1 Characteristics of all studies included in the meta-analysis

Ref.	Country	Type	Patients(n)	Male (%)	Median follow-up time (months)
Blay et al[26], 2021	France	RCT	85	55	6.3
Janku et al[27], 2020	American	Cohort	142	58.5	10.6
Bauer et al[31], 2022	Germany	RCT	226	61.5	7.9
Li et al[32], 2023	China	RCT	54	36	13.8

Table 2 Quality assessment using the Jadad Scale for randomized controlled trial

Ref.	Type	Random allocation	Randomized hiding	Double-blind method setting	Exit and loss to follow-up	Score
Blay et al[26], 2021	RCT	2	2	2	2	8
Bauer et al[31], 2022	RCT	1	2	2	2	7
Li et al[32], 2023	RCT	2	2	1	2	7

RCT: Randomized controlled trial.

Table 3 Quality assessment using the Newcastle-Ottawa Scale for cohort studies

Ref.	Selection				Comparability	Outcome			Score
	Representativeness of the exposed cohort	Selection of the nonexposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts
Janku et al[27], 2020	1	0	1	1	1	1	0	1	6